Evidence map›Paper›PMID 39738986›Full record

ArticleDiscover oncology2024

A novel histone acetylation-associated gene signature with prognostic value in Ewing sarcoma.

Anshun Wu, Fayin Liu, Lei Zhou, Runyi Jiang, Shangjiang Yu, Zihuan Zhou, Qi Zhang, Qian Zhang, Dongjie Jiang, Shaohui He and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Anshun Wu *Clinical Medical College, North China University of Science and Technology, Tangshan, 063210, China.
Fayin Liu *Department of Orthopedics, Zibo Orthopaedics Hospital, Zibo, 255000, China.
Lei Zhou *Department of Orthopaedic Oncology, Spinal Tumor Center, No. 905 Hospital of PLA Navy, Second Affiliated Hospital of Naval Medical University, Naval Medical University, Shanghai, 200003, China.
Runyi JiangDepartment of Orthopaedic Oncology, Spinal Tumor Center, No. 905 Hospital of PLA Navy, Second Affiliated Hospital of Naval Medical University, Naval Medical University, Shanghai, 200003, China.
Shangjiang YuSchool of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai, 200093, China.
Zihuan ZhouDepartment of Orthopaedic Oncology, Spinal Tumor Center, No. 905 Hospital of PLA Navy, Second Affiliated Hospital of Naval Medical University, Naval Medical University, Shanghai, 200003, China.
Qi ZhangDepartment of Orthopaedic Oncology, Spinal Tumor Center, No. 905 Hospital of PLA Navy, Second Affiliated Hospital of Naval Medical University, Naval Medical University, Shanghai, 200003, China.
Qian ZhangDepartment of Orthopaedic Oncology, Spinal Tumor Center, No. 905 Hospital of PLA Navy, Second Affiliated Hospital of Naval Medical University, Naval Medical University, Shanghai, 200003, China.
Dongjie Jiang *Department of Orthopaedic Oncology, Spinal Tumor Center, No. 905 Hospital of PLA Navy, Second Affiliated Hospital of Naval Medical University, Naval Medical University, Shanghai, 200003, China. jdjspine@163.com.
Shaohui He *Department of Orthopaedic Oncology, Spinal Tumor Center, No. 905 Hospital of PLA Navy, Second Affiliated Hospital of Naval Medical University, Naval Medical University, Shanghai, 200003, China. heshaohui1025@163.com.
Haifeng Wei *Clinical Medical College, North China University of Science and Technology, Tangshan, 063210, China. weihfspine@126.com.

Funding

Funding of Shanghai Changning Health Commission 2023QN25National Natural Science Foundation of China 82203401Pujiang Talent Program of Shanghai 22PJD086
6 · The paper itself

Abstract

Histone acetylation is an important epigenetic modification, modulating the development of many tumors. However, the functions of most histone acetylation-related genes (HARGs) and their prognostic values in Ewing sarcoma (EWS) remain unclear. The current study aimed to investigate the prognostic values and potential functions of HARGs in EWS. After collecting EWS patients with mRNA sequencing data from the Gene Expression Omnibus (GEO) database and a list of HARGs from previous studies, Cox regression and Least Absolute Shrinkage and Selection Operator (LASSO) regression were performed to construct a prognostic gene signature based on HARGs. Then, four HARGs (TAF4, ATF2, HDAC2 and OGA) composed a formula to calculate risk score for each patient in the training cohort. Based on median risk score, all patients were classified into low- and high-risk group, and patients with high-risk score had a poor survival outcome (p < 0.001). The 1-, 2-,3- and 5-year AUC (0.853, 0.886,0.909and 0.833, respectively) showed the good ability of this signature to predict the prognoses of EWS patients. In addition, distinct functional enrichment and immune-related pathways were also observed in two risk groups. All results were validated in an external cohort from two dataset in GEO database. Moreover, it was found that silencing HDAC2 expression in EWS cells significantly suppressed the cell viability and migration capability. In conclusion, this is the first study to detect the prognostic values of HARGs in EWS patients, further developing a good prognostic signature based on HARGs, and HDAC2 might be an oncogene in the development of EWS.

Indexed as

Ewing sarcomaHDAC2Histone acetylationPrognostic signature

Identifiers

PMID39738986
PMCPMC11685356

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.